Success Metrics

Active Trials

0(0%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Other(3)

Detailed Status

unknown2

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

unknown267%

suspended133%

Recent Activity

0 active trials

Showing 3 of 3

unknownphase_1

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

NCT05771883

unknownphase_1

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

NCT05805943

suspendedphase_1

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

NCT04746131

Clinical Trials (3)

Showing 3 of 3 trials

NCT05771883Phase 1

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Unknown

NCT05805943Phase 1

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Unknown

NCT04746131Phase 1

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Suspended

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3